Search tips
Search criteria 


Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. 2009 October; 53(10): 4565–4567.
Published online 2009 July 20. doi:  10.1128/AAC.00436-09
PMCID: PMC2764197

Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland[down-pointing small open triangle]

Anna Baraniak, Radosław Izdebski, Małgorzata Herda, Janusz Fiett, Waleria Hryniewicz, and Marek Gniadkowski*
National Medicines Institute
00-725 Warsaw, Poland
Izabela Kern-Zdanowicz
Institute of Biochemistry and Biophysics
02-106 Warsaw, Poland
Krzysztof Filczak
Central Hospital of Ministry of Interior and Administration
02-507 Warsaw, Poland

Plasmidic KPC β-lactamases in gram-negative pathogens are of the highest clinical and epidemiologic concern, conferring resistance to all β-lactams, including carbapenems (15, 18). The main KPC producer is Klebsiella pneumoniae, but other species are being identified as well (15). Strains with KPCs spread rapidly and cause outbreaks; in hospitals on the east coast of the United States and in Israel, they have already become endemic (2, 3, 10, 14, 17). Recently, more countries have reported the presence of these organisms, in some cases as a result of importation (15).

On 19 May 2008, a 56-year-old patient with no travel history was admitted to a cardiology ward in a Warsaw hospital (H1) with ischemic cardiomyopathy and several comorbidities. He had been transferred from another hospital with pneumonia of unknown etiology and was treated empirically with ceftriaxone and ciprofloxacin until 28 May. The eradication of pneumonia was asserted by clinical criteria. However, without a bladder catheter, the patient developed a urinary tract infection caused by K. pneumoniae (isolate 2337/08) on 23 May. With the imipenem MIC for the isolate being 2 μg/ml, the organism was classified by the Vitek 2 Expert system (bioMérieux, Marcy l'Etoile, France) as being resistant and having the “extended-spectrum β-lactamase-plus-carbapenemase” phenotype. The next such isolate (2338/08) was recovered from urine collected on 28 May, 2 days after the start of treatment with amikacin. Environmental sampling, conducted on the same day in the patient's room, yielded a similar K. pneumoniae isolate (2641/08) from a basin. On 3 June, the eradication of the urinary tract infection by amikacin was proven through clinical criteria and the results of microbiological examination, and the patient was discharged without having been tested for fecal carriage. On 6 June, he was admitted to a cardiology center (H2) for heart transplantation. At the time of admission, samples of his urine, stool, and sputum were analyzed. K. pneumoniae (isolate 2639/08) was cultured only from the stool specimen. The patient was kept under strict isolation without antimicrobial treatment, and his stool was examined each day during the first week and then twice a week during the remaining hospitalization. The stool samples were analyzed by standard procedures for enteric organisms, after which species identification was performed with the ATB ID32E test (bioMérieux) and susceptibility testing with drugs including imipenem, meropenem, and ertapenem was carried out by disk diffusion according to the CLSI guidelines (6). On 27 June, the sample was finally free of K. pneumoniae, and this result was confirmed in several subsequent analyses. On 17 July, the patient, disqualified for heart transplantation, was discharged from center H2 without symptoms of infection.

Analyzed by Etest (AB Biodisk, Solna, Sweden), the isolates showed multidrug resistance, including reduced susceptibilities to carbapenems (Table (Table1).1). In the spectrophotometric assay (17), products of bacterial sonication hydrolyzed imipenem in an EDTA-independent manner. Isoelectric focusing (1) revealed β-lactamases with a pI of 7.6 (probably the SHV-like chromosomal enzymes) and three others with pIs of 8.2, ~6.8, and 5.4. Since pI ~6.8 specifies the KPC-2/KPC-3 β-lactamases, a PCR (13) and sequencing were performed, which identified the blaKPC-2 genes (19). PCR mapping revealed that they resided on one of the Tn4401 transposon variants, Tn4401a (12). Mating was performed with Escherichia coli A15 Rifr (1); transconjugants were selected with 100 μg/ml rifampin (rifampicin) and 0.5 μg/ml imipenem or 2 μg/ml ceftazidime. On the imipenem plate, only isolate 2641/08 gave a transconjugant with KPC-2 and the pI 5.4 enzyme, identified by PCR and sequencing (9) as TEM-1. In contrast, on the ceftazidime plates, all isolates yielded transconjugants which had only the pI 8.2 enzyme, identified by PCR and sequencing (9) to be extended-spectrum β-lactamase SHV-12. Plasmid DNA from the isolates, purified with the Qiagen plasmid midi kit (Qiagen, Hilden, Germany), was used for electroporation of E. coli DH5α and then analyzed on plates with 0.5 μg/ml imipenem. Transformants with KPC-2 and TEM-1 were obtained for all isolates. PstI fingerprinting (9) showed three plasmid molecules in each isolate, two of which segregated individually into SHV-12-producing transconjugants and KPC-2/TEM-1-producing transformants (Fig. (Fig.1).1). Sizes of the plasmids were evaluated by calibration of the fingerprint bands and by pulsed-field gel electrophoresis (PFGE) analysis of total DNA digested with nuclease S1 (16). Plasmids with the blaSHV-12 gene and with the blaKPC-2 and blaTEM-1 genes were ~40 and ~110 kb, respectively, whereas those likely to be without bla genes were ~200 kb. The PCR-based replicon typing (5) yielded products only with primers specific for the replicon FIIAS, carried on Salmonella virulence plasmids (5). Moreover, this method worked only with DNA from the K. pneumoniae isolates and not with that from the transconjugants and transformants, indicating that the amplicons corresponded to the plasmids likely to be without bla genes. Sequencing of the amplicons revealed their ca. 97% identity to fragments of repA genes on plasmids pKPN3 and pKPN4 from K. pneumoniae MGH78578 (GenBank accession numbers CP000648 and CP000649) and only ca. 79% identity to plasmid pSLT from Salmonella enterica serovar Typhimurium LT2 (11). K. pneumoniae isolates were indistinguishable by PFGE analysis of their DNA cuts with the XbaI restriction enzyme (9). Multilocus sequence typing (8; classified them as sequence type 258 (ST258), recently identified for KPC producers in Norway and Sweden, mostly of Greek and Israeli origins (16).

FIG. 1.
PstI (Fermentas, Vilnius, Lithuania) fingerprinting of plasmid DNA from the K. pneumoniae clinical isolates, E. coli DH5α transformants producing KPC-2 and TEM-1 (T), and E. coli A15 transconjugants producing SHV-12 (R). Molecular size markers: ...
Susceptibilities of the K. pneumoniae isolates and of the E. coli transconjugants obtained in the study

This first report on KPC producers in Poland documents their continuing spread. The strain belonged to a widespread clonal group with single-locus variants ST11, ST258, and ST270 (7; The previous ribotyping- and PFGE-based observations of the high clonality of KPC-producing K. pneumoniae (4, 14, 17) and the multilocus sequence typing data from this and the Scandinavian work (16) suggest a prominent role for this group in KPC dissemination.


We are thankful to Alessandra Carattoli for helpful suggestions and to Cara Horowitz for the critical reading of the manuscript. This work was part of the activities of the MOSAR integrated project (LSHP-CT-2007-037941) supported by the European Commission under the Life Science Health priority of the 6th Framework Programme (WP2 Study Team) and was partially financed by grant no. PBZ-MNiSW-04/I/2007 and 934/6.PR/UE/2009/7 from the Polish Ministry of Science and Higher Education.


[down-pointing small open triangle]Published ahead of print on 20 July 2009.


1. Bauernfeind, A., H. Grimm, and S. Schweighart. 1990. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection 18:294-298. [PubMed]
2. Bratu, S., D. Landman, R. Haag, R. Recco, A. Eramo, M. Alam, and J. Quale. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165:1430-1435. [PubMed]
3. Bratu, S., M. Mooty, S. Nichani, D. Landman, C. Gullans, B. Pettinato, U. Karamudi, P. Tolaney, and J. Quale. 2005. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49:3018-3020. [PMC free article] [PubMed]
4. Bratu, S., P. Tolaney, U. Karamudi, J. Quale, M. Mooty, S. Nichani, and D. Landman. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, N.Y.: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128-132. [PubMed]
5. Carattoli, A., A. Bertini, L. Villa, V. Falbo, K. L. Hopkins, and E. J. Threlfall. 2005. Identification of plasmids by PCR-based replicon typing. J. Microbiol. Methods 63:219-228. [PubMed]
6. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement, M100-S18. CLSI, Wayne, PA.
7. Damjanova, I., A. Tóth, J. Pászti, G. Hajbel-Vékony, M. Jakab, J. Berta, H. Milch, and M. Füzi. 2008. Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type β-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005—the new ‘MRSAs’? J. Antimicrob. Chemother. 62:978-985. [PubMed]
8. Diancourt, L., V. Passet, J. Verhoef, P. A. Grimont, and S. Brisse. 2005. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J. Clin. Microbiol. 43:4178-4182. [PMC free article] [PubMed]
9. Fiett, J., A. Pałucha, B. Miączyńska, M. Stankiewicz, H. Przondo-Mordarska, W. Hryniewicz, and M. Gniadkowski. 2000. A novel complex mutant β-lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum β-lactamase-producing klebsiellae. Antimicrob. Agents Chemother. 44:1499-1505. [PMC free article] [PubMed]
10. Landman, D., S. Bratu, S. Kochar, M. Panwar, M. Trehan, M. Doymaz, and J. Quale. 2007. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, N.Y. J. Antimicrob. Chemother. 60:78-82. [PubMed]
11. McClelland, M., K. E. Sanderson, J. Spieth, S. W. Clifton, P. Latreille, L. Courtney, S. Porwollik, J. Ali, M. Dante, F. Du, S. Hou, D. Layman, S. Leonard, C. Nguyen, K. Scott, A. Holmes, N. Grewal, E. Mulvaney, E. Ryan, H. Sun, L. Florea, W. Miller, T. Stoneking, M. Nhan, R. Waterston, and R. K. Wilson. 2001. Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature 413:852-856. [PubMed]
12. Naas, T., G. Cuzon, M.-V. Villegas, M.-F. Lartigue, J. P. Quinn, and P. Nordmann. 2008. Genetic structures at the origin of acquisition of the β-lactamase blaKPC gene. Antimicrob. Agents Chemother. 52:1257-1263. [PMC free article] [PubMed]
13. Navon-Venezia, S., I. Chmelnitsky, A. Leavitt, M. J. Schwaber, D. Schwartz, and Y. Carmeli. 2006. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob. Agents Chemother. 50:3089-3101. [PMC free article] [PubMed]
14. Navon-Venezia, S., A. Leavitt, M. J. Schwaber, J. K. Rasheed, A. Srinivasan, J. B. Patel, Y. Carmeli, and the Israeli KPC Kpn Study Group. 2009. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob. Agents Chemother. 53:818-820. [PMC free article] [PubMed]
15. Nordmann, P., G. Cuzon, and T. Naas. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236. [PubMed]
16. Samuelsen, Ø., U. Naseer, S. Tofteland, D. H. Skutlaberg, A. Onken, R. Hjetland, A. Sundsfjord, and C. G. Giske. 2009. Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. J. Antimicrob. Chemother. 63:654-658. [PubMed]
17. Woodford, N., P. M. Tierno, Jr., K. Young, L. Tysall, M.-F. I. Palepou, E. Ward, R. E. Painter, D. F. Suber, D. Shungu, L. L. Silver, K. Inglima, J. Kornblum, and D. M. Livermore. 2004. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York medical center. Antimicrob. Agents Chemother. 48:4793-4799. [PMC free article] [PubMed]
18. Yigit, H., A. M. Queenan, G. J. Anderson, A. Domenech-Sanchez, J. W. Biddle, C. S. Steward, S. Alberti, K. Bush, and F. C. Tenover. 2001. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45:1151-1161. [PMC free article] [PubMed]
19. Yigit, H., A. M. Queenan, J. K. Rasheed, J. W. Biddle, A. Domenech-Sanchez, S. Alberti, K. Bush, and F. C. Tenover. 2003. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob. Agents Chemother. 47:3881-3889. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)